Directed new share issue in Xspray Pharma AB (SE) — SEK 92 million

Carnegie acted as bookrunner in the directed new share issue of 1,370,000 shares at a subscription price of SEK 67 per share. Xspray is a product development company with several product candidates in clinical development. Xspray employs a patent protected technology platform to develop improved and generic versions of already marketed drugs, primarily protein kinase inhibitors (PKIs) for cancer treatment. December 2018.